Clinical Trial Update: Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Advair Diskus to Serevent Diskus in COPD exacerbations has completed, sponsored by GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)
• SEREVENT DISKUS (SALMETEROL XINAFOATE)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED